Published in Arch Neurol on November 01, 2008
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue. Cell (2013) 4.02
Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain (2010) 3.84
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology (2012) 2.49
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J (2010) 2.26
Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol (2012) 2.20
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Changing perspectives regarding late-life dementia. Nat Rev Neurol (2009) 2.04
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci (2013) 2.01
Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology (2012) 2.01
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia (2012) 1.90
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology (2011) 1.70
β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage (2010) 1.68
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol (2012) 1.64
Alzheimer disease. Dis Mon (2010) 1.64
Arterial stiffness and β-amyloid progression in nondemented elderly adults. JAMA Neurol (2014) 1.63
Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia (2011) 1.60
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron (2013) 1.54
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected]. Medicine (Baltimore) (2014) 1.50
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47
Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology (2010) 1.46
Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol (2012) 1.44
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol (2009) 1.42
Targeting the low-hanging fruit of neurodegeneration. Neurology (2014) 1.41
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain (2011) 1.41
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol (2011) 1.40
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology (2015) 1.40
Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. BMC Neurol (2015) 1.38
CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex (2011) 1.38
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther (2009) 1.37
Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta (2011) 1.36
The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol (2009) 1.36
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
Poor decision making is a consequence of cognitive decline among older persons without Alzheimer's disease or mild cognitive impairment. PLoS One (2012) 1.35
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
Aging, the central nervous system, and mobility. J Gerontol A Biol Sci Med Sci (2013) 1.32
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med (2010) 1.27
Neuropathology of non-Alzheimer degenerative disorders. Int J Clin Exp Pathol (2009) 1.27
Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. Arch Gen Psychiatry (2012) 1.26
Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci (2014) 1.26
Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease. Mt Sinai J Med (2010) 1.26
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol (2013) 1.25
Partial volume correction in quantitative amyloid imaging. Neuroimage (2014) 1.24
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Neural compensation in older people with brain amyloid-β deposition. Nat Neurosci (2014) 1.21
Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One (2013) 1.21
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology (2013) 1.18
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Computer assessment of mild cognitive impairment. Postgrad Med (2009) 1.18
Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp (2012) 1.17
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
Cognitive decline impairs financial and health literacy among community-based older persons without dementia. Psychol Aging (2013) 1.17
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging (1997) 7.54
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol (1998) 3.20
Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol (1999) 3.20
Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging (1992) 3.05
PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain (2007) 2.88
Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl (1998) 2.83
Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol (2006) 2.68
Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology (2000) 2.64
Stroop performance in healthy younger and older adults and in individuals with dementia of the Alzheimer's type. J Exp Psychol Hum Percept Perform (1996) 2.42
Adult age differences in working memory. Psychol Aging (1989) 2.15
Response suppression, initiation and strategy use following frontal lobe lesions. Neuropsychologia (1996) 1.94
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage (2006) 1.65
Research evaluation and diagnosis of possible Alzheimer's disease over the last two decades: II. Neurology (2000) 1.57
Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet (1995) 1.51
Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology (2001) 1.50
Does it all go together when it goes? The Nineteenth Bartlett Memorial Lecture. Q J Exp Psychol A (1993) 1.49
Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord (2000) 1.36
Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology (2000) 1.29
The relation of white matter hyperintensities to cognitive performance in the normal old: education matters. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn (2006) 1.07
Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res (1996) 1.02
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Maintenance treatment of major depression in old age. N Engl J Med (2006) 7.61
The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry (2009) 6.71
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Treatment of complicated grief: a randomized controlled trial. JAMA (2005) 5.15
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
Chronic traumatic encephalopathy in a National Football League player. Neurosurgery (2005) 4.67
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med (2003) 4.30
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA (2009) 4.06
Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology (2004) 3.94
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med (2011) 3.73
Vascular cognitive impairment. Lancet Neurol (2003) 3.73
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry (2004) 3.17
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol (2002) 3.07
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry (2004) 2.87
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol (2003) 2.70
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA (2009) 2.59
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Chronic traumatic encephalopathy in a national football league player: part II. Neurosurgery (2006) 2.40
Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry (2013) 2.30
Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci (2008) 2.30
Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. Am J Psychiatry (2008) 2.25
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol (2004) 2.21
Role of intense affects in predicting short-term risk for suicidal behavior: a prospective study. J Nerv Ment Dis (2010) 2.17
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17